FROM A PATIENT ADVOCATE'S PERSPECTIVE
MARY "DICEY" SCROGGINS TRAVEL AWARD WINNER
FROM MORGAN NEWMAN, MSW
COMMUNITY ENGAGEMENT LIAISON, CERVIVOR, INC.

In 2016, I was diagnosed with a metastatic recurrence of cervical cancer. I never would have imagined being where I'm at today as a patient advocate. I didn't know how my voice could help make a difference. Nor would I have expected to have these incredible opportunities provided by NRG Oncology and The GOG Foundation, Inc (GOG).

It was an honor to receive the Mary "Dicey" Scroggins Travel Award from the GOG. Through this scholarship, I was able to attend working committee meetings and learn from the dedicated professionals leading the work in developing clinical trials. This made me feel like I was truly part of the process and that these Oncologists, Researchers, etc. wanted to learn from my experience as a patient as well.

Sometimes these feelings are hard to put into words. It can be overwhelming to experience this as a patient advocate but it's something I appreciate and I
PRESIDENTIAL ANNOUNCEMENT

The GOG Foundation, Inc. Board Elects
Thomas J. Herzog, MD, as President Elect.

At the NRG Oncology Summer Meeting on July 21, 2022, The GOG Foundation, Inc. (GOG-F) Board of Directors elected Thomas J. Herzog, MD as its next President, succeeding Larry J. Copeland, MD who has served in this role since 2017. Under Dr. Copeland’s leadership, the GOG-F has experienced unprecedented growth in its clinical trials program, particularly in GOG-Partners (GOG-P), including a greatly expanded clinical trials portfolio, further expansion and engagement of its investigator base, development of a clinical trial mentorship program, and multiple educational initiatives focused on novel agents, clinical trial design and clinical trial execution. Dr. Herzog will serve as the President-Elect of the GOG-F for one-year, assuming the role as President after the July 2023 meeting. Dr. Copeland will remain in office until July 2023 and continue to be involved in the day-to-day activity as Immediate Past President of the organization.

Dr. Herzog shares, “I am incredibly humbled and deeply honored to be elected as the President-Elect of the GOG-F. I want to thank the Nominating Committee and Foundation Board for their support. I am so excited to work with such an outstanding and dedicated team. I especially want to thank Dr. Copeland for his mentorship throughout my career as well as his outstanding vision and leadership of our organization during his tenure. He has created a culture that places the best interests of our patients as the central focus in the mission to deliver tomorrow’s care today through innovative practice changing clinical trials. Operationalizing this mission has required an enormous effort by our leaders, our staff, and our enrolling sites. As President, I am committed to continue to foster this outstanding culture in supporting our mission and to build upon our success, while conquering new challenges ahead for GOG-F and for our patients that we are so honored to serve.”

Click here to view the full press release.

SPECIAL RECOGNITION

The GOG Foundation, Inc. and GOG Partners would like to congratulate the following authors for their outstanding presentations at the 2022 ASCO Annual Meeting:

[List of authors]

2022 ASCO ANNUAL MEETING

[Logo]

[Logo]
GOG Clinical Trial Oral Presentations:

- **Domenica Lorusso, MD, PhD, GOG-3024 (InnovaTV205)/ ENGOT Cx8**: Tisotumab vedotin (TV) + pembrolizumab (pembro) in first-line (1L) recurrent or metastatic cervical cancer (r/mCC): Interim results of ENGOT Cx8/GOG 3024/innovaTV205.


- **Bradley J, Monk, MD, GOG-3020 (ATHENA) / ENGOT-ov45**: A randomized, double-blind, phase 3 trial evaluating rucaparib monotherapy versus placebo as maintenance treatment following response to first-line platinum-based chemotherapy in ovarian cancer.

GOG Clinical Trial Posters Presentations:

- **Leslie M. Randall, MD, MS, FACS, GOG-3032 (MOONSTONE)**: Interim analysis of a phase 2 study of niraparib + dostarlimab in patients (pts) with platinum-resistant ovarian cancer (PROC).

- **Ignace Vergote, MD, PhD, ENGOT-cx8/ GOG-3024 (InnovaTV 205)**: Trial in progress update on ENGOT-cx8/GOG-3024/innovaTV 205: Addition of a new cohort with first-line (1L) tisotumab vedotin (TV) + pembrolizumab (pembro) + carboplatin (carbo) ± bevacizumab (bev) in recurrent/metastatic cervical cancer (r/mCC).

- **Kristin Leigh Bixel, MD, BS, GOG-3043 (ROCC)**: A randomized non-inferiority trial of robotic versus open radical hysterectomy for early-stage cervical cancer.

- **Richard T. Penson, MD, MRCP, GOG-3018 (OVAL) VB-111-701**: Pivotal study of ofra-vec (VB-111) combined with paclitaxel versus paclitaxel for treatment of platinum-resistant ovarian cancer.

- **Thomas J. Herzog, MD, GOG-3063 (ARTISTRY-7)**: A phase 3, multicenter study of nemvaleukin alfa in combination with pembrolizumab versus chemotherapy in patients (pts) with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer.

- **Susana N. Banerjee, PhD, MA, MBBS, FRCP, ENGOT-ov60/ GOG-3052 (RAMP 201)**: A phase 2 study of VS-6766 (RAF/MEK clamp) alone and in combination with defactinib (FAK inhibitor) in recurrent low-grade serous ovarian cancer (LGSOC).

- **Angeles Alvarez Secord, MD, MHSc, GOG-3035 (FLORA-5)**: Frontline chemotherapeutic (paclitaxel-carboplatin-oregovomab [PCO] versus chemotherapy (paclitaxel-carboplatin-placebo [PCP]) in patients with advanced epithelial ovarian cancer (EOC)—Phase III, double-blind, placebo-controlled, global, multinational study.

- **Brian M. Slomovitz, MD, GOG-3064 (KEYNOTE-C93)/ ENGOT-en15**: A phase 3, randomized, open-label study of first-line pembrolizumab versus platinum-doublet chemotherapy in mismatch repair deficient advanced or recurrent endometrial carcinoma.
The GOG Foundation, Inc. is thrilled to announce the New Horizons Gynecologic Research Fund website page is now available to accept donations.

Donations from individuals, corporations, and foundations directly fund the GOG educational and research initiatives. Together, we collaborate with industry to find new treatments, and more effective prevention while promoting excellence in scientific research in the field of gynecologic malignancies.

Each donation received will go directly to provide:
- Much needed resources to effectively work towards the prevention and treatment of gynecologic malignancies
- Accessible research funding
- Ability to mentor New Investigators through fellowship awards
- Opportunity to raise public awareness through education and research
- Translational medicine initiatives across the disease committees

Click the Support Our Mission button below to make a donation today!

---

**FEATURED CLINICAL TRIALS**

**GOG-3020 (ATHENA)**

Press Release

June 6, 2022: Rucaparib As First-Line Maintenance Treatment Significantly Improves Progression-Free Survival In Women With Advanced Ovarian Cancer In Primary Efficacy Analyses Regardless Of BRCA Mutation And HRD Status

[Click Here](#) to view the full Press Release

**GOG-0212**

Press Release

June 28, 2022: Additional taxane maintenance therapy does not successfully improve overall survival for women with advanced ovarian, peritoneal, and tubal cancers.

[Click Here](#) to view the full Press Release.
The International Gynecologic Cancer Society (IGCS) invites you to the IGCS 2022 Annual Global Meeting to be held Sept. 29 – Oct. 1 at the Javits Center in New York, NY. The Annual Gynecologic Cancer Survivor-Caregiver Advocacy Summit will be held the day prior on Sept. 28th.

The IGCS Annual Global Meeting delivers a variety of educational sessions including master sessions on ovarian, cervix, uterine, and vulvar cancers, debates on hot topics, and surgical sessions featuring the latest technology and techniques. Plenary sessions present the latest developments in research, practice, and treatment of gynecological cancers from experts around the world.

IGCS President, Dr. Robert Coleman has announced this year’s Presidential Plenary will focus on Collaborative Solutions to Achieve Equitable Gynecologic Cancer Care through Innovation, Research, and Advocacy. Supported in part by The GOG Foundation, Inc. and GOG Partners, the Presidential Plenary panelists include Dr. Douglas Lowy, Dr. Tashanna Myers, and Annie Ellis. Make sure to watch this special video message from Dr. Coleman to learn more and register here today!

GOG PARTNERS PAST EVENTS ENDURING MATERIALS

Check out the GOG Past Events web page for on demand symposia recordings and meeting materials including the following recently added Independent Satellite
LET'S GET SOCIAL

What GOG Means to ME
The GOG Foundation, Inc. launched a “What GOG Means to ME” social media campaign and we would like you to participate.

As a participant in this campaign, you will be highlighted on our social media feeds (Twitter, Instagram, LinkedIn and Facebook). If you would like to participate, please email Lindsey Moeller at lmoeller@gog.org with no more than a 35-word quote indicating what GOG means to you. We will feature your quote along with the following information on our GOG Social Media platforms throughout the year.

- **Quote**: No more than 35 words indicating what GOG means to you, examples can include: research, clinical trials, networking.
- **Current Headshot (Jpg or PNG format)**
- **Current Title/Role**
- **Institution**
- **Social Tags**: Please provide how we can find you on each of the social platforms so we can tag you when we post.

We appreciate your participation!

Become a GOG Social Media Agent
The GOG Foundation is looking for members that are savvy with social media to become GOG Social Media Agents! Throughout the year our communications staff will invite our agents to participate in social media campaigns for meetings, education and special events. If you are interested in becoming a GOG Social Media Agent, please email Lindsey Moeller at lmoeller@gog.org and include the following information:

- Current Headshot (Jpg or PNG format)
- Current Title/Role
- Institution
- Social Tags
How Can We Help?

The GOG Partners Connection Quarterly Newsletter is produced by the GOG Foundation Communications Committee.

Please contact us at info@gog.org with any questions or suggestions regarding future content.